2Harris TB, Ferrucc IL, Tilacy RP, et al. Mortality risk associated with elevated interleukin-6 and C-reactive protein in old age. Am J Med, 1999,196:506-512
3Nonoeaki K, Fuller GM, Fuentes NL, et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology, 1995,136 :Z143-2149
4Fishman D,Faulds G,Jeffery R,et al. The effect of novel polymorphisms in the interleukln-6 (IL-6)gene on IL- 6transcription and plasma/L26 levels, and an association with systemic2onset juvenile chronic arthritis. J Clin Invest, 1998, 102(7) : 1369-1376
6Ota N, Nakajima T, Nakazawa I, et al. A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density. Hum Genet, 2001,46 ( 5 ) : 267-272
7Humphries SE, Luong LA, Ogg MS, et al. The interleukin-6- 174 G/C promoter polymorphism is associated with riskof coronary heart disease and svstolic blood pressure inheahhy men. Eur Heart J,2001,22 :2243-2252
8Georges JL, Loukaei V, Poirier O, et al. Interleukin-6 genepolymorphism and susceptibility to myocardial infarction:the ectim study. J Mol Med ,2001,79:300-305
9Basso E, Lowe GD, Rumley A, et al. Interleukin-6-174GC polymorphism and risk of coronary heart disease in west of scotland coronary prevention study. Arterioseler Thromb Vase Biol,2002,22:599-604
10Nauck M, Winkelmann BR, Michael M. The interleukin-6G (-174) Cpromoter polymorphism in the LURIC cohort:noassociation with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med,2002,80:507-513
同被引文献47
1Lagathu C, Bastard yP, Auclair M, et al. Chronic interleukin-6 treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochcm Biophys Res Con- nun,2010,311:372-379.
2Jang Y, Kim OY, H yun YJ, et al. Interleukin-6 -572 c/G poly- morph ismassoeiation with inflammatory variables in Korean men with coronary artery disease. J Transl Res, 2008, 151 (3): 154-161.
3DandonaP, Aliada A, Mohanty P, et al. Insulin inhibits intranue- lear nuclear factor kappa B and stimulates Ikappa B in mononuelear cellsin obese subjects: evidence for an anti-inflammatory effect? Clin Endoerinol Metab. 2009. 86:3257-3265.
4Campbell IL, Cutri A, Wilton A, et al, Evidence for IL-6 produc- tion by and effects on the pancreatic beta cell. Immunol, 2009, 143 . 1188-1191.
5Huth C, Ulig T, Herder C, et al. Joint analysis of individual par- ticipants data from 17 studies on the association of the IL-6 variant 174 g > C with circulating glucose levels, in terleukin-6 levels, and body mass index. Ann In tern Med, 2008, 8(27) : 1-21.
6Koh SJ, Jang Y, H yun YJ, et al. The interleukin-6 -572 c > G promoter polymorphism is associated with type 2 diabetes risk in Koreans. Clin Endocrinol, 2008, 7 (20) : 542-549.
7Koh SJ, Jang YS, Hyun YJ, et al. Interleukin-6(IL-6) -572 c/G promoter polymorphism is associated with type 2 diabetes risk in Koreans. Clinical Endocrinology, 2009, 70(2) : 238-244.
8Berg KK, Madsen HO, Garred P, et al. The additive contribution from inflammatory genetic markers on the severity of cardiovascular disease. Scand J Immunol, 2009, 69(1) : 36--42.
9Manginas A, Tsiavou A, Chaidaroglou A, et al. Inflammatory cy- tokine gene variants in coronary artery disease patients in Greece. Coron Artery Dis, 2008, 19(8) : 575-582.
10Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6 : depot differ- ence and regulation by glucocorticoid. J Clin Endocfinol Metab, 2008,83:847-850.
